Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG)
BackgroundThe PACIFIC and GEMSTONE-301 trials established consolidation immunotherapy post-chemoradiotherapy for unresectable stage III NSCLC, but 22–30% of patients fail initial chemoradiotherapy, precluding consolidation. PACIFIC-2 and CheckMate 73L …